Home > Healthcare > Pharmaceuticals > Finished Drug Form > Fibrate Drugs Market

Fibrate Drugs Market Share

Report ID: GMI8450
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Fibrate Drugs Market Share

The fibrate drugs industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Fibrate Drugs Market Companies

Some of the eminent market participants operating in the fibrate drugs industry include:

Aurobindo Pharma Limited
Abbott Laboratories
Cipla Inc.
IOL Chemicals and Pharmaceuticals Limited
Lupin Limited
Mylan N.V.
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Unnati Pharmaceuticals Pvt Ltd.
Zydus Lifeciences Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for fibrate drugs was valued at around USD 3.1 billion in 2023 and is estimated to reach over USD 4.8 billion by 2032, driven by the increasing prevalence of cardiovascular disease.

Clofibrate segment generated a decent revenue in 2023 and is estimated to account for USD 2.1 billion by 2032 as they help in the management of lipid disorders and reducing the risk of cardiovascular events.

North America market was worth USD 1.2 billion in 2023 and is predicted to witness substantial growth through 2032, driven by a robust investment in drug R&D, catering to the needs of elderly population.

Aurobindo Pharma Limited, Abbott Laboratories, Cipla Inc., IOL Chemicals and Pharmaceuticals Limited, Lupin Limited, Mylan N.V., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. are some of the major industry contenders.